The impact of childhood RSV infection on children's and parents' quality of life: a prospective multicenter study in Spain
Eva Díez-Gandía, Carla Gómez-Álvarez, Mónica López‐Lacort, Cintia Muñoz-Quiles, Isabel Úbeda-Sansano, Javier Díez‐Domingo, Alejandro Orrico‐Sánchez, Study collaborators, Fernando Calvo Rigual, E. Suárez Vicent, Carmen Mañes, Elena Martí, Teresa Cerdán, Antoni Soriano‐Arandes, Lucia Losada Pavón, Airam Álvarez Sánchez, Gemma Ricós Furió, Tomás Pérez Porcuna, Noemí Magro Benito, Javier Martínez Díaz, Jessica Ortiz, Ana Cristina Mangas, Mónica Fernández García, Patricia Rovira, Marta Urgellés, Marta Pozuelo
Abstract
BACKGROUND: Several immunisation candidates against RSV are in late-stage clinical trials. To evaluate the benefits of a potential vaccination programme, both economic and health benefits will be needed. Health benefits are usually measured in Health-related Quality of Life (HRQoL) loss using standardised questionnaires. However, there are no RSV-specific questionnaires validated for children under 2 years, in whom most RSV episodes occur. Therefore, HRQoL estimates are taken from literature or inadequate tools. We determined HRQoL loss and direct costs due to an RSV episode in children younger than 2 years and their caregivers during a month of follow up, using a new questionnaire administered online. METHODS: An observational prospective multicentre surveillance study was conducted in children aged younger than two years. Children were recruited from 8 primary care centres and 1 hospital in the Valencia region and Catalonia (Spain). RSV-positive cases were obtained by immunochromatographic test. HRQoL was assessed using a new ad-hoc 38 item-questionnaire developed. Parents of infected children completed 4 questionnaires at four timepoints (day 0, 7, 14 and 30) after diagnosis. RESULTS: 117 children were enrolled in the study and 86 (73.5%) were RSV + . Median (interquartile range; IQR) scores were 0.52 (0.42-0.68), 0.65 (0.49-0.79), 0.82 (0.68-0.97) and 0.94 (0.81-1), for days 0, 7, 14 and 30, respectively. Compared to total recovery (Q30), HRQoL loss was 37.5%, 31.5% and 8.9% on days 0, 7 and 14 since diagnosis of the disease. The total median cost per patient (including treatments) was €598.8 (IQR: 359.63-2425.85). CONCLUSIONS: RSV had almost 40% impact on HRQoL during the first week since onset of symptoms and the median cost per episode and patient was about €600. These results represent a substantial input for health-economic evaluations of future RSV-related interventions such as vaccination.